Oppenheimer analyst Steven Lichtman raised the firm’s price target on RxSight to $72 from $61 and keeps an Outperform rating on the shares. The firm notes the company’s Q1 sales at $29.5M beat its/Street’s prior $27.6M estimates led by higher-than-expected LAL sales. RxSight also raised 2024 sales guidance to $132M-$137M from $128M-$135M. Gross margin was also a standout in Q1 and 2024 gross margin guidance was raised to 68%-70% from 65%-67% previously, Oppenheimer adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight, Inc. Reports First Quarter 2024 Financial Results
- Rxsight, Inc. (RXST) Q1 Earnings Cheat Sheet
- RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
- RxSight launches its newest light adjustable lens, the LAL+
- RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
Questions or Comments about the article? Write to editor@tipranks.com